Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Liver cancer is associated with chronic inflammation, which is linked to immune dysregulation, disordered metabolism, and aberrant cell proliferation. Nucleoside triphosphate diphosphohydrolase-1; (CD39/ENTPD1) is an ectonucleotidase that regulates extracellular nucleotide/nucleoside concentrations by scavenging nucleotides to ultimately generate adenosine. These properties inhibit antitumor immune responses and promote angiogenesis, being permissive for the growth of transplanted tumors. Here we show that Cd39 deletion promotes development of both induced and spontaneous autochthonous liver cancer in mice. Loss of Cd39 results in higher concentrations of extracellular nucleotides, which stimulate proliferation of hepatocytes, abrogate autophagy, and disrupt glycolytic metabolism. Constitutive activation of Ras-mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR)-S6K1 pathways occurs in both quiescent Cd39 null hepatocytes in vitro and liver tissues in vivo. Exogenous adenosine 5′-triphosphate (ATP) boosts these signaling pathways, whereas rapamycin inhibits such aberrant responses in hepatocytes. Conclusion: Deletion of Cd39 and resulting changes in disordered purinergic signaling perturb hepatocellular metabolic/proliferative responses, paradoxically resulting in malignant transformation. These findings might impact adjunctive therapies for cancer. Our studies indicate that the biology of autochthonous and transplanted tumors is quite distinct. (Hepatology 2013)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“More specifically, in these settings, Ras and phosphatidylinositol-3-OH kinase (PI3K) pathways converge to activate mTOR in response to nutrients and to mitogens.(2) The role of purinergic signaling(3,4) in hepatocarcinogenesis is unexplored.”
BackgroundMathew, R., Karantza-Wadsworth, V., & White, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2254 · Cited by 1,798 · cited 4×
“This is an antitumor mechanism linked to various cancers, including HCC.23,30 In this study, we provide evidence that mTOR-mediated suppression of autophagy is modulated through purinergic signaling pathways, in response to extracellular nucleotides and further regulated by CD39 in a tightly controlled manner (Figs.”
BackgroundInfluentialSenescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621 · cited 1×
“Recent studies have also noted that murine hepatocytes enter a senescence program triggered by excessive proliferative signaling, which has features (at least in part) of the cellular phenotype observed in these current studies in Cd39-null hepatocytes.(31) Senescent liver cells are subject to surveillance and immune…”
BackgroundmTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488 · cited 2×
“Cunningham et al.26 have shown that mTOR controls mitochondrial oxidative function by formation of a transcriptional complex with YY1 (Ying Yang 1)- PGC-1a (peroxisome-proliferator activated receptor coactivator-1a).”
BackgroundCarracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381 · cited 1×
“Recently, a novel mTORC1-MAPK feedback loop (mediated by way of the S6K1-PI3K-Ras-ERK pathway) has also been identified in both normal cells and cancer cells.(28) Rapalog exposure unfortunately disrupts crucial negative feedback mechanisms and results in subsequent activation of PI3K-AKT and/or PI3K-MAPK pathways.”
BackgroundTyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
Hitosugi, T., Kang, S., Vander Heiden, M. G., Chung, T.-W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000431 · Cited by 784 · cited 2×
“that tyrosine phosphorylation of PKM2 may serve as a critical glycolytic switch in cancer cells.(24) As shown in Fig.”
BackgroundFang, M., Shen, Z., Huang, S., Zhao, L., Chen, S., Mak, T. W., & Wang, X. (2010) · Cell · doi:10.1016/j.cell.2010.10.010 · Cited by 222
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Self-citationTargeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Targeting adenosine for cancer immunotherapy
Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 543
Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α
Mascanfroni, I. D., Takenaka, M. C., Yeste, A., Patel, B., Wu, Y., Kenison, J. E., Siddiqui, S., Basso, A. S., Otterbein, L. E., Pardoll, D. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3868 · Cited by 439
Self-citation
Metadata
- Authors
- Sun, X., Han, L., Seth, P., Bian, S., Li, L., Csizmadia, E., Junger, W. G., Schmelzle, M., Usheva, A., Tapper, E. B., Baffy, G., Sukhatme, V. P., Wu, Y., & Robson, S. C.
- Venue
- Hepatology
- Published
- 2013-01
- Volume
- 57
- Issue
- 1
- Pages
- 205-216
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1966919402
- Cited by
- 87
- References
- 7
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice. https://app.cochat.ai/papers/10.1002/hep.25989
- The paper
- Sun, X., Han, L., Seth, P., Bian, S., Li, L., Csizmadia, E., Junger, W. G., Schmelzle, M., Usheva, A., Tapper, E. B., Baffy, G., Sukhatme, V. P., Wu, Y., & Robson, S. C. (2013). Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice. Hepatology. https://doi.org/10.1002/hep.25989
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.